What are the most common mistakes with SS-31 (Elamipretide / MTP-131)?
The most common SS-31 (Elamipretide / MTP-131) mistakes are expecting fast effects (it's cumulative); running short cycles and quitting before adaptation; underdosing for therapeutic context. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for SS-31 (Elamipretide / MTP-131) is limited.
Common SS-31 (Elamipretide / MTP-131) mistakes
- Expecting fast effects (it's cumulative)
- Running short cycles and quitting before adaptation
- Underdosing for therapeutic context
References
- Elamipretide in primary mitochondrial myopathy (MMPOWER trials) — Karaa A et al., Neurology, 2018
- Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER — Thompson WR, Manuel R, Abbruscato A, et al. — Genetics in Medicine, 2024
- FORZINITY (elamipretide hydrochloride) injection — FDA Prescribing Information — FDA / DailyMed (Stealth BioTherapeutics), 2025
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on SS-31 (Elamipretide / MTP-131)
Full SS-31 (Elamipretide / MTP-131) breakdownSS-31 (Elamipretide / MTP-131) what it's used forSS-31 (Elamipretide / MTP-131) side effectsSS-31 (Elamipretide / MTP-131) how to take itSS-31 (Elamipretide / MTP-131) who should avoid itSS-31 (Elamipretide / MTP-131) half-lifeSS-31 (Elamipretide / MTP-131) how long to workSS-31 (Elamipretide / MTP-131) legal statusSS-31 (Elamipretide / MTP-131) how it worksAsk the AI Coach
Last updated 2026-06-15.